A Phase 2 Randomized Study Investigating the Efficacy and Safety of Myostatin Antibody LY2495655 versus Placebo in Patients Undergoing Elective Total Hip Arthroplasty.

@article{Woodhouse2016AP2,
  title={A Phase 2 Randomized Study Investigating the Efficacy and Safety of Myostatin Antibody LY2495655 versus Placebo in Patients Undergoing Elective Total Hip Arthroplasty.},
  author={Lisa Woodhouse and Rahul Gandhi and Stuart J Warden and Serge Poiraudeau and Stephen L Myers and Charles T. Benson and Lingling Hu and Qasim I Ahmad and P Linnemeier and Eduardo Vilar Gomez and Olivier B{\'e}nichou},
  journal={The Journal of frailty & aging},
  year={2016},
  volume={5 1},
  pages={62-70}
}
BACKGROUND Total hip arthroplasty relieves joint pain in patients with end stage osteoarthritis. However, postoperative muscle atrophy often results in suboptimal lower limb function. There is a need to improve functional recovery after total hip arthroplasty. OBJECTIVES To assess safety and efficacy of LY2495655, a humanized monoclonal antibody targeting myostatin, in patients undergoing elective total hip arthroplasty. DESIGN Phase 2, randomized, parallel, double-blind, 12-week clinical… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Similar Papers

Loading similar papers…